Compare ResMed Inc. (RMD) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Tidewater Inc — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while Tidewater Inc trades at $92.78 (market cap $4.58B). The key difference: ResMed Inc. is far larger — about 7× Tidewater Inc's market cap, and ResMed Inc. pays a 1.19% dividend while Tidewater Inc pays none. Which is the better fit depends on your goals.
| RMD | TDW | |
|---|---|---|
Market Cap | $31.89B | $4.58B |
Sector | Health | Utilities |
52-Week High | $283.28 | $100.61 |
52-Week Low | $182.82 | $47.29 |
Enterprise Value | $31.24B | $4.62B |
Dividend Yield | 1.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
TDW trades at $92.00, down 2.4% on the day, with a bullish technical signal and support near $91. The company reported a net income of $334.66M in 2025, though 2026 earnings have missed expectations in two of the last three quarters. Recent news includes the completion of the Wilson Sons Ultratug acquisition (Business Wire, 2026-08-31), potentially expanding its offshore service capabilities.
The stock offers a 14.7% upside to the consensus price target of $105.50, supported by strong institutional interest, but faces risks from volatile earnings and competitive pressures in the energy sector. Profit margins are expected to compress in 2026, requiring careful monitoring of operational execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
